A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
- Sponsor
- Excelsior
- Study ID
- NCT03299829
- Status
- Completed
Conditions
- Trientine Treatment for Wilson's Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Trientine — DRUGTrientine is a chelating agent for removing the copper from the body
Study Details
This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients
Key Dates
- First listed
- Oct 3, 2017
- Start date
- Jan 10, 2018
- Status verified
- Aug 2020
- Primary completion
- Jun 30, 2019
- Completion
- Dec 30, 2019
Study Design
- Enrollment
- 48 participants (actual)
Primary Outcome Measure
The improvement in liver function [ Time Frame: Up to 1 year ]